Use of the RTX secretion system to achieve heterologous...

Details Use of the RTX secretion system to achieve heterologous... Use of the RTX secretion system to achieve heterologous...

2006-05-23

2006-05-23

Wax, Robert A. (Department: 1653)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S069700, C530S350000

Reexamination Certificate

active

07049423

ABSTRACT:
Compositions and methods for secreting large heterologous polypeptides are described.

REFERENCES:
patent: 4882278 (1989-11-01), Mekalanos
Allo et al., “Prevention of Clindamycin-Induced Colitis in Hamsters by . . . ” Gastroenterology 76(2):351-355, 1979.
Butterton et al., “Heterologous Antigen Expression inVibrio choleraeVector Strains” Infection and Immunity 63(7):2689-2696, 1995.
Bulletin of the World Health Organization, U.S. Institute of Med. Washington, D.C., National Academy Press, vol. 68(3):303-312, 1990.
Corthier et al., “Protection against Experimental Pseudomembranous Colitis in Gnotobiotic . . . ” Infection and Immunity 59(3):1192-1195, 1991.
Dillon et al., “Involvement of Ras-Related Rho Proteins in the Mechanisms of . . . ” Infection and Immunity 63(4):1421-1426, 1995.
Dove et al., “Molecular Characterization of theClostridium difficileToxin A Gene” Infection and Immunity 58(2):480-488, 1990.
Fullner et al., “Vibrio cholerae-Induced Cellular Responses of Polarized T84 . . . ” Infection and Immunity 69(10):6310-6317, 2001.
Fullner et al., “In vivo covalent cross-linking of cellular actin by theVibrio choleraeRTX toxin” The EMBO Journal 19(20):5315-5323, 2000.
Gentschev et al., “SalmonellaStrain Secreting Active Listeriolysin Changes . . . ” Infection and Immunity 63(10):4202-4205, 1995.
Herrington et al., “Toxin, Toxin-Coregulated Pili, and thetoxRRegulon . . . ” J. Exp. Med. 168:1487-1492, 1988.
Kelly et al., “Human Colonic Aspirates Containing Immunoglobulin A Antibody . . . ” Gastroenterology 102:35-40, 1992.
Ketley et al., “The effects ofClostridium difficilecrude toxins and toxin A . . . ” J. Med. Microbiol. 24:41-52, 1987.
Kim et al., “Immunization of Adult Hamsters againstClostridium difficile-Associated . . . ” Infection and Immunity 55(12):2984-2992, 1987.
Johnson et al., “Neutralization of a Bacterial Enterotoxin by Systemic IGA . . . ” J. Immunol. 150:117A Abstract #657, 1993.
Krivan et al., “Cell Surface Binding Site forClostridium difficileEnterotoxin: . . . ” Infection and Immunity 53(3):573-581, 1986.
Leung et al., “Treatment with Intravenously Administered Gamma Globulin . . . ” J. of Pediatrics 118(4):633-637, 1991.
Levine et al., “New Knowledge on Pathogenesis of Bacterial Enteric Infections . . . ” Microbiological Rev. 47(4):510-550, 1983.
Levine et al., “Duration of Infection-Derived Immunity to Cholera” J. of Infectious Diseases 143(6):818-820, 1981.
Lin et al., “Identification of aVibrio choleraeRTX toxin gene cluster that is . . . ” Proc. Nat'l. Acad. Sci. USA 96:1071-1076, 1999.
Lyerly et al., “Clostridium difficile: Its Disease and Toxins” Clin. Microbiol. Rev. 1(1):1-18, 1988.
Mekalanos et al., “Cholera toxin genes: nucleotide sequence, deletion analysis . . . ” Nature 306(5943):551-557, 1983.
Mitty et al., “Clostridium difficileDiarrhea: Pathogensis, Epidemiology, and Treatment” The Gastroenterologist 2(1):61-69, 1994.
Saroso et al.; “A controlled field trial of plain and aluminium hydroxide-adsorbed cholera . . . ” Bulletin of the WHO 56(4):619-627, 1978.
Sauerborn et al., “Nucleotide Sequence ofClostridium difficileToxin A” Nucleic Acids Res. 18(6):1629-1630, 1990.
Swerdlow et al., “Cholera in the Americas” JAMA 267(11):1495-1499, 1992.
Tauxe et al., “Epidemic Cholera in Latin America” JAMA 267(10):1388-1390, 1992.
Taylor et al., “Development of a Live, Oral, Attenuated Vaccine Against El Tor Cholera” J. of Infectious Diseases 170(6):1518-1523, 1994.
Tucker et al., “Toxin A ofClostridium difficileBinds to the Human Carbohydrate . . . ” Infection and Immunity 59(1):73-78, 1991.
Von Eichel-Streiber et al., “Clostridium difficiletoxin A carries a C-terminal repetitive . . . ” Gene 96:107-113, 1990.
Warny et al., “Human Antibody Response toClostridium difficileToxin A . . . ” Infection and Immunity 62(2):384-389, 1994.
Wren et al., “Antigenic Cross-Reactivity and Functional Inhibition by Antibodies . . . ” Infection and Immunity 59(9):3151-3155, 1991.

Affiliated with

Also associated with

Rating

Use of the RTX secretion system to achieve heterologous... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of the RTX secretion system to achieve heterologous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the RTX secretion system to achieve heterologous... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3612593